Article
San Francisco - Inamed Corp. received approval from the U.S. Food and Drug Administration to compete against what it considers a formidable foe - its own ZyDerm and ZyPlast products.
Bridging Therapeutic Innovation and Dermatology
The Cutaneous Connection: Intervening in AD Progression for Pediatric Patients
Nektar Therapeutics Completes Enrollment for Phase 2b REZOLVE-AD Trial of Rezpegaldesleukin
The Cutaneous Connection: Navigating Systemic Therapies in Atopic Dermatitis
State-of-the-State Update: Chronic Hand Eczema
Researchers Develop Recommendations for Hyaluronic Acid Filler Placement in Cases of Hollowness, Volume Deficits